Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 356 participants.

Also called NCT01541943

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 356 participants (enrolled count) (from the registry)
Sponsor
HanAll BioPharma Co., Ltd. (from the registry)
Registry
  • NCT NCT01541943
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01541943. Randomized; double masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2014-11 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of HL-040XC in Essential Hypertension and Hyperlipidemia
Condition
Essential Hypertension
Condition
Hyperlipidemia
Intervention (Drug)
Atorvastatin
Intervention (Drug)
Losartan
Intervention (Drug)
Placebo
Intervention (Drug)
HL-040XC
Lead sponsor
HanAll BioPharma Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct01541943
Content hash
0b62b36c7a3373f39b90b7ba7be2adea71e22c789e3d63ca21e36234c23759b8